Hepler Broom, LLC

Category Archives: Pay-for-delay

“Pay-for-Delay” Patent Settlements Coming Under Increased Antitrust Scrutiny

April 1, 2013

On January 17, 2013, the Federal Trade Commission (FTC) issued a report revealing an increase in “pay-for-delay” or “reverse-payment” patent settlements between brand-name pharmaceutical companies and their generic counterparts These controversial settlements typically involve a brand-name drug manufacturer who is granted a drug patent which gives the company the exclusive right to sell the drug […]